brand logo

Am Fam Physician. 2005;71(4):663

to the editor: We were pleased to see the recent review on cutaneous leishmaniasis by Markle and Makhoul.1 Cutaneous leishmaniasis is a significant health concern for the U.S. Armed Forces with more than 650 cases diagnosed over a nine-month period, primarily acquired in Iraq.2 It is common for family physicians or other primary care clinicians to make the initial diagnosis. Given the number of Reserve and National Guard personnel serving in this conflict, it is important for physicians who care for these patients to recognize and be aware of management guidelines because they may see returning military servicemen who did not seek care initially or had late activation of their infection (incubation period can vary from 30 days to six months).3

The authors note that trauma is a potential source of disease reactivation. Returning soldiers infected with cutaneous leishmaniasis should be alerted that tattoos can lead to local dissemination of disease over the tattoo site.4

Since 1978, Walter Reed Army Medical Center (WRAMC) in Washington, D.C., and, more recently, Brooke Army Medical Center (BAMC) in San Antonio, are the military sites for treatment of leishmaniasis. The authors state that sodium stibogluconate (Pentostam) is available from the Centers for Disease Control and Prevention, but it is important to mention that this medication also is available under protocol at WRAMC and BAMC. Service members with deployment-related infection for up to two years after the end of deployment can be referred to these centers for care. Questions should be referred to the Department of Defense Deployment Health Clinical Helpline, telephone: 866-559-1627, orhttp://www.pdhealth.mil. Health care professionals may refer patients to the treatment centers at WRAMC, telephone: 202-782-1663, or BAMC, telephone: 210-916-5554. Assistance with diagnostic support can be obtained from the military Leishmania Diagnostic Laboratory in Silver Spring, Md., at 301-319-9956.

While pentavalent antimony for 20 days remains the standard treatment duration for cutaneous leishmaniasis (when Pentostam is elected for treatment), a recent clinical trial demonstrated that 10 days of treatment was effective and associated with fewer side effects.5 A controlled trial of heat treatment recently has been completed at WRAMC.

Email letter submissions to afplet@aafp.org. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors. Letters submitted for publication in AFP must not be submitted to any other publication. Letters may be edited to meet style and space requirements.

This series is coordinated by Kenny Lin, MD, MPH, deputy editor.

Continue Reading


More in AFP

More in Pubmed

Copyright © 2005 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See https://www.aafp.org/about/this-site/permissions.html for copyright questions and/or permission requests.